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Edited by Judit Ova´diAbstract The pyruvate uptake rate in inverted submitochon-
drial vesicles prepared from rat liver was optimized and further
characterized; the potential inhibitory eﬀects of the anticonvul-
sive drug valproic acid or 2-n-propyl-pentanoic acid (VPA),
D4-valproic acid or 2-n-propyl-4-pentenoic acid and the respec-
tive coenzyme A (CoA) conjugates were studied in the presence
of a proton gradient. All tested VPA metabolites inhibited the
pyruvate uptake, but the CoA esters were stronger inhibitors
(40% and 60% inhibition, respectively, for valproyl-CoA and
D4-valproyl-CoA, at 1 mM). At the same concentration, the spe-
ciﬁc inhibitor 2-cyano-4-hydroxycinnamate decreased the pyru-
vate uptake rate by 70%. The reported inhibition of the
mitochondrial pyruvate uptake may explain the signiﬁcant
impairment of the pyruvate-driven oxidative phosphorylation in-
duced by VPA.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Inverted submitochondrial membranes1. Introduction
The oxidative metabolism of pyruvate in mitochondria is a
highly regulated process which depends on the import and/or
diﬀusion of this 2-oxoacid from the cytosolic compartment.
Any xenobiotic that may interfere with this transport will com-
promise mitochondrial functioning and thus energy metabo-
lism. Valproic acid (VPA, 2-n-propyl-pentanoic acid) is a
powerful antiepileptic drug, with speciﬁc indications for many
forms of epilepsy and many types of seizures, aﬀecting children
or adults.Abbreviations: VPA, valproic acid or 2-n-propyl-pentanoic acid; D4-
VPA, D4-valproic acid or 2-n-propyl-4-pentenoic acid; CoA, coenzyme
A; VP-CoA, valproyl-CoA; D4-VP-CoA, D4-valproyl-CoA; ISMV,
inverted submitochondrial vesicles; IMM, inner mitochondrial mem-
brane; UCP, uncoupling protein; CHC, 2-cyano-4-hydroxycinnamate;
SEM buﬀer, sucrose/EGTA/MOPS buﬀer; MES, 2-[N-morpholino]eth-
anesulfonic acid; HEPES, N-(2-hydroxyethyl)piperazine-N 0-(2-ethane-
sulfonic acid); DCIP, 2,6-dichloroindophenol
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doi:10.1016/j.febslet.2008.08.028Previous in vitro studies from our group showed that VPA
and its metabolites induce a striking decrease in the pyru-
vate-driven mitochondrial oxygen consumption and ATP syn-
thesis [1]. One hypothesis raised by these results was the
putative interference of VPA or its biotransformation products
with the mitochondrial pyruvate uptake. Besides its complete
oxidation, the transport of pyruvate across mitochondrial
membranes is an essential process for many other metabolic
pathways, such as glucose oxidation, lipogenesis, gluconeogen-
esis and amino acid metabolism [2].
Since the early 1970s, many proteins that transport metabo-
lites, nucleotides and co-factors across the inner mitochondrial
membrane (IMM) have been identiﬁed [3]. The mitochondrial
ADP/ATP carrier, the uncoupling proteins (UCPs), the phos-
phate, oxoglutarate/malate, citrate and carnitine/acylcarnitine
carriers among many others, have been identiﬁed, puriﬁed
and characterized [3,4].
The transport of pyruvate was ﬁrst described by Papa et al.
in 1971, in rat liver mitochondria, and it was shown that this
process is coupled to proton symport [5]. Later, in 1974, Hale-
strap and Denton identiﬁed a potent and speciﬁc inhibitor of
pyruvate transport, i.e. 2-cyano-4-hydroxycinnamate (CHC)
suggesting the existence of a speciﬁc carrier involved in the
pyruvate transport across the IMM [6–10].
The transport of pyruvate in bovine heart mitochondria was
also characterized [11] and the transport assays were per-
formed using a reconstituted system of solubilized submito-
chondrial particles incorporated into liposomes [11,12].
Using this system, the CHC-sensitive pyruvate-exchange reac-
tion had substrate and inhibitor characteristics similar to
those observed in mitochondria. A 34 kDa protein was de-
scribed as being responsible for the pyruvate uptake both in
bovine heart [11] and rat liver mitochondria [13]. In yeast,
the pyruvate carrier was identiﬁed in a fraction containing
two polypeptides of apparent molecular mass of 26 and
50 kDa [14].
In 2003, Hildyard et al. identiﬁed the mitochondrial pyru-
vate carrier in Saccharomyces cerevisiae, by measuring the
inhibitor-sensitive pyruvate uptake in isolated mitochondria
from mutant yeast strains in which the genes coding for each
of the members of the mitochondrial carrier family, were dis-
rupted one-by-one [2,15]. Mitochondria isolated from the yeast
mutant YIL006w exhibited a speciﬁc loss of pyruvate uptake.
However, the gene product of YIL006w, named Ndt1p, wasblished by Elsevier B.V. All rights reserved.
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casts doubt about the function of this protein as a mitochon-
drial pyruvate carrier in yeast.
In plants, several biochemical and molecular studies have
suggested the presence of a speciﬁc carrier in the IMM which
mediates the electroneutral uptake of pyruvate, driven by a
pH gradient. This protein was found to be inhibited by CHC
and other molecules, giving support to the fact that (1) plant
pyruvate transport has biochemical features similar to mam-
malian pyruvate transport and that (2) it involves a carrier
rather than pyruvate entering by means of diﬀusion [17].
The UCPs are also specialized transporters located in the
IMM. They allow passive proton transport through the
IMM, reducing the proton electrochemical gradient built up
by the respiratory chain [18,19]. Diﬀerent isoforms of these
proteins have been identiﬁed in mammals (UCP1 present in
brown adipocytes, UCP2 in several tissues, UCP3 in brown
adipose tissue and muscle, UCP4 and UCP5 in brain) [19].
Moreover, it has been reported that UCP1 exhibits the widest
substrate speciﬁcity among the other homologous anion trans-
porters, being also able to transport pyruvate [20]. The liver is
the organ in which expression of UCPs is the lowest, at least
under basal conditions [21]. Only a low level of expression of
UCP2 was detected in the adult rat liver [21], as other UCP
genes are silent in this tissue.
The hypothesis that the mitochondrial pyruvate uptake
could be aﬀected by VPA, has been proposed in one single
study, using brain mitochondria [22] where a competitive inhi-
bition mechanism was reported. Nevertheless, under in vivo
conditions VPA will probably undergo rapid activation to its
coenzyme A (CoA)-ester and will also be metabolized. This
prompted the study described in this paper, in which we stud-
ied the eﬀect of VPA and the respective CoA-ester [23,24], as
well as D4-valproic acid or 2-n-propyl-4-pentenoic acid (D4-
VPA), its main microsomal product [25], and D4-valproyl-
CoA (D4-VP-CoA) [26]. The results presented herein provide
evidence that VPA, and in particular some speciﬁc metabolites
that are most probably more abundant in cytosol and/or mito-
chondria than the parent molecule [24], inhibit the uptake of
pyruvate in inverted submitochondrial vesicles (ISMV),
accounting for the mitochondrial dysfunction that has been
associated with valproate.2. Materials and methods
2.1. Materials
Sucrose, BSA, CHC, valinomycin, L-lactate, VPA and other chem-
icals were obtained from SIGMA Aldrich. The sodium salt of [1-14C]-
pyruvic acid (250 lCi, speciﬁc activity 27 mCi/mmol, 243 lCi/mg,
M = 111 g/mol) was obtained from Amersham Biosciences. Ultima-
Gold liquid scintillation solution was purchased from Packard.2.2. Synthesis of valproyl-CoA (VP-CoA), D4-VPA and D4-VP-CoA
VP-CoA and D4-VP-CoA were synthesized according to published
procedures [24] from VPA and D4-VPA, respectively. D4-VPA was ob-
tained by chemical synthesis following a reported procedure [27]. VP-
CoA and D4-VP-CoA were puriﬁed by solid phase extraction, and its
purity checked using HPLC with diode array detection (>95%).2.3. Isolation of rat liver mitochondria
The study was conducted according to the National Guidelines for
the care and use of laboratory animals (Faculty of Pharmacy animals
laboratory).Adult male Wistar rats (200–300 g) were starved for 18–20 h. After
cervical displacement, the livers were immediately removed and rinsed
into ice-cold homogenization medium containing 250 mM sucrose,
0.5 mM ethylene glycol-bis(b-aminoethyl ether)-N,N,N 0,N 0-tetraacetic
acid, 5 mM 3-[N-morpholino]propanesulfonic acid, pH 7.4 (sucrose/
EGTA/MOPS buﬀer, SEM buﬀer). Rat liver mitochondria were pre-
pared according to a published procedure [24]. Brieﬂy, after mincing
and 2–3 washings with SEM buﬀer (at 4 C), the chopped liver was
homogenized in a precooled Teﬂon pestle glass homogenizer. From
here onwards the whole process was conducted at 4 C. The homoge-
nate was centrifuged at 600 · g (10 min) and the obtained post-nuclear
supernatant was further centrifuged at 3600 · g (10 min). The obtained
pellet was suspended in SEM buﬀer and after one last round of centri-
fugation at 2700 · g (10 min), the mitochondria were ﬁnally resus-
pended in the homogenization medium (25–50 mg/ml).
2.4. Preparation of ISMV
ISMV were obtained from the above prepared rat liver mitochon-
dria according to a published procedure [28] with minor modiﬁcations.
Mitochondria were resuspended in 0.25 M sucrose and 1 g/l BSA keep-
ing the temperature at 4 C. The suspension was gently homogenized
with a dounce tissue grinder (6–7 strokes) and centrifuged at
27000 · g (15 min). The obtained pellet was resuspended in 5 ml of
sonication medium (225 mM sucrose, 10 mM NaH2PO4, 1 g/l BSA,
pH 7.4) and sonicated 3 · 30 s. The obtained vesicle suspension was di-
luted in 25 ml of sonication medium and centrifuged at 23500 · g
(10 min). The supernatant was further centrifuged at 44000 · g
(60 min). The ISMV were obtained after resuspending the ﬁnal pellet
in 2 ml of a medium containing 225 mM sucrose, 10 mM Tris–HCl,
1 mM EDTA and 1 g/l BSA (pH 7.4) and passing it through a 21 g nee-
dle. Protein was measured using the Bradford method [29], with BSA
as a reference substance. This sonication technique provides an homo-
geneously oriented vesicle preparation with a percentage of inversion
ranging from 90% to 96% [28,30].
2.5. Characterization of ISMV preparations
2.5.1. Succinate dehydrogenase activity. The purity of the mem-
brane vesicle preparation was assessed by the measurement of succi-
nate dehydrogenase activity as described elsewhere [31]. The reaction
mixture contained 50 mM KPi, 0.015% 2,6-dichloroindophenol
(DCIP), 2 mM KCN and 15 mM sodium succinate. Reactions were
started by adding 50 ll of sample (approx. 40 lg of protein) and the
decrease in absorbance was measured at 600 nm (total volume 1 ml).
The enzyme activity was calculated using eDCIP600 nm = 21 mM
1 cm1.
2.5.2. Vesicle size determination. Vesicle size of all prepared batches
was determined by quasi-elastic light scatter (QELS) using a particle
sizer (BI-90 Brookhaven Instruments). An application of this tech-
nique in the determination of vesicular sizes has been published [32].
2.5.3. Osmotic response by stopped-ﬂow light-scatter. In order to as-
sure the sealing and leakiness of the membrane vesicles, the osmotic re-
sponse of ISMV (swelling and shrinking) was assessed by stopped-ﬂow
light scattering in which aliquots of ISMV were subjected to hypo- and
hyperosmotic shocks. Experiments were performed on a HI-TECH
Scientiﬁc PQ/SF-53 stopped-ﬂow apparatus, which has a 2 ms dead
time, interfaced with an IBM PC/AT compatible 80386 microcom-
puter, at a controlled temperature. ISMV in the isotonic resuspension
buﬀer (0.1 ml, 0.4 mg/ml protein) were mixed with an equal amount of
hypo-, iso- or hyper-osmotic mannitol solutions at 23 C to reach dif-
ferent inwardly or outwardly directed gradients of solute (swelling and
shrinking; osmotic gradients 62.5, 0, 125 and 375 mosM). The time-
course of 90 scattered light intensity at 400 nm was followed until a
stable light-scattered signal was obtained. The change in light scatter
intensity (I) of the ISMV preparation after an osmotic shock
(DI = I0  I1) is related to their vesicular volume change [33] and thus,
it can be used as a tool to assure vesicle integrity. The osmolarities of
all solutions were measured using a cryometric automatic semi-micro
osmometer (Knauer, Germany).2.6. Pyruvate uptake measurements
The rate of the radiolabeled substrate [1-14C]-pyruvate uptake by
ISMV was measured in the presence or absence of an inwardly directed
proton gradient. Prior to the uptake, the ISMV were equilibrated in
100 mM KCl, 20 mM N-(2-hydroxyethyl)piperazine-N 0-(2-ethanesul-
fonic acid) (HEPES), pH 7.4, by passing the vesicle preparation
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take was measured at 4 C after incubation of the ISMV suspension
(ﬁnal concentration range: 0.1–5.7 mg/ml, pH 7.4) with 5 ll of
240 mM 2-[N-morpholino]ethanesulfonic acid (MES) containing
0.066 lCi of [1-14C]-pyruvate and 10 lM valinomycin, resulting in an
extravesicular pH of 5.5 and a ﬁnal concentration of 0.02–0.67 mM
pyruvate (ﬁnal volume: 30 ll). The reaction was stopped by diluting
the sample with ice-cold stop solution (84 mM KCl, 17 mM HEPES,
40 mM MES, 1 mM CHC, pH 5.5) at appropriate times (0–60 s), fol-
lowed by rapid ﬁltration in a vacuum assembly through Osmonics ﬁl-
ters (0.45 lm pore size), and 2–3 washing steps with the same cold stop
solution [34]. The ﬁlters were dried at room temperature, and the ves-
icle-associated radioactivity in the ﬁlters was determined by liquid scin-
tillation counting in a Packard Tri-Carb 2100 TR Liquid Scintillation
Analyzer. The non-speciﬁc binding of the isotope to the surface of the
vesicles as well as to the ﬁlters was determined by a similar pyruvate
uptake experiment but without incubation. An average value was ob-
tained from triplicate measurements (blanks), which was subtracted in
further corresponding experiments.
Pyruvate exchange in the absence of a proton gradient was assayed
under similar experimental conditions, replacing the incubation med-
ium by 100 mM KCl, 20 mM HEPES containing [1-14C]pyruvate
and 10 lM valinomycin, resulting in an extravesicular pH of 7.4.
The stop solution consisted of 100 mM KCl, 20 mM HEPES and
1 mM CHC, ﬁnal pH 7.4, and the subsequent steps were performed
accordingly.2.7. Pyruvate uptake measurements in the presence of inhibitors
The eﬀect of VPA, VP-CoA, D4-VPA and D4-VP-CoA on the mito-
chondrial pyruvate uptake was assessed by pre-incubating the ISMV
(2 mg/ml) with puriﬁed solutions of these compounds at various con-
centrations (0.5–2 mM), for 3 min, prior to the uptake assay. CHC,10 100 1000
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Fig. 1. (A) ISMV size determination by quasi-elastic light scattering (QELS
mean diameter of 293 ± 12 nm (n = 10). (B) Record of a typical stopped-ﬂow
was suddenly exposed to diﬀerent osmotic shocks (62.5, 0, 125 and 375 m
Dependence of the total change in light scatter (DI = I0  I1), related to the t
gradient (mosM).a powerful and speciﬁc inhibitor of the mitochondrial pyruvate carrier
[8], was used as a positive control. The eﬀect of lactate was also studied
using a similar concentration range. The subsequent pyruvate uptake
measurement driven by an inwardly directed proton gradient was as-
sayed as described above, incubating the vesicles for 5 s with [1-14C]-
pyruvate at various concentrations (0.07, 0.17 and 0.67 mM ﬁnal con-
centrations).
2.8. Data analysis
The kinetic parameters of the mitochondrial pyruvate transport
activity were determined by non-linear regression analysis using the
SigmaPlot 9.0 Technical Graphing Software.3. Results
3.1. Characterization of the inner ISMV
Puriﬁed ISMV were prepared from mitochondria isolated
from rat liver homogenates by diﬀerential centrifugation.
The activity of the marker enzyme succinate dehydrogenase,
an enzymatic complex bound to the IMM that participates
in both the citric acid and the mitochondrial electron transport
chain (complex II), was measured. The obtained values were
0.013 ± 0.002 U/mg protein and 0.023 ± 0.01 U/mg protein,
respectively, determined in the initial mitochondrial homoge-
nates and in the ISMV suspension, indicating a two-fold vesi-
cle enrichment after puriﬁcation.
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dient (mosM)
0 0.1 0.2 0.3 0.4 0.5
Osmotic Gradient
-62.5
125
375
0
Sc
at
te
re
d 
lig
ht
 in
te
ns
ity
(a
rb
itr
ar
y 
un
its
)
Time (sec)
B
(mosM)
). Vesicles in the resuspension buﬀer were homogeneous in size with a
experiment where the light scatter intensity from an ISMV suspension
osM). The time course of volume change was followed for 0.5 s. (C)
otal volume change of the ISMV vesicles, for a speciﬁc applied osmotic
[14C]-pyruvate (mM)
[14
C
]-p
yr
uv
at
e 
up
ta
ke
 (n
m
ol
/m
g.
s) pHout < pHin
pHout = pHin
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
0.014
0.012
0.010
0.008
0.006
0.004
0.002
0.000
Fig. 3. Eﬀect of the proton gradient in the pyruvate uptake in ISMV as
function of increasing substrate concentration. The uptake was driven
by an inwardly directed proton gradient (pHout < pHin) (closed circles
d), and without proton gradient (pHout = pHin) (opened circles s).
The data shown are mean ± S.D. of triplicates of two independent
experiments.
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(n = 10) and as depicted, a unimodal distribution was achieved,
demonstrating that the vesicles were homogeneous in size.
Fig. 1B shows the recordings of a typical stopped-ﬂow
experiment where the light scatter intensity from an ISMV sus-
pension suddenly exposed to diﬀerent solutions (iso-, hyper-
and hypo-osmotic) was monitored for 0.5 s. A remarkable
increase in scattered light was observed when vesicles were sub-
jected to hyper-osmotic gradients of 125 and 375 mosM, in
contrast to the light scatter decrease for the hypo-osmotic gra-
dient 62.5 mosM, in agreement with vesicle shrinking and
swelling. No change in scattered light was observed when ves-
icles were mixed with iso-osmotic buﬀer (absence of osmotic
gradient). The dependence of the total change in light scatter
(DI) for a given osmotic gradient applied (mosM) is shown
in Fig. 1C and demonstrates that the vesicles behaved like
osmometers for the chosen osmolarity range, therefore assur-
ing vesicle integrity.
3.2. Pyruvate uptake measurements in ISMV
3.2.1. Time course and substrate dependence. Pyruvate up-
take was assayed in vitro using puriﬁed ISMV by measuring
the uptake of [1-14C]-pyruvate by these vesicles. The rate of la-
belled substrate accumulation inside the vesicles was measured
through a rapid ﬁltration technique and isotope scintillation
counting.
As shown in Fig. 2, a time-dependent uptake of radiolabeled
pyruvate was observed in ISMV, in the presence of an in-
wardly directed proton gradient (pHout 5.5 < pHin 7.4) sug-
gesting apparent ﬁrst order kinetics. Moreover, virtually no
pyruvate uptake was observed in the absence of a proton gra-
dient (pHout = pHin 7.4). The rate of pyruvate uptake in the
prepared vesicles was linearly dependent on the protein con-
tent (0–6 mg/ml, data not shown). Considering the above re-
sults, a reaction time of 5 s and a protein content of 2 mg/ml
were selected for all subsequent studies.
The concentration dependence of pyruvate uptake was also
studied in ISMV, in the presence and absence of a driving pro-
ton gradient. Fig. 3 shows the uptake rate as function of the
pyruvate concentration. From a double reciprocal plot andTime (s)
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Fig. 2. Uptake of [14C]-pyruvate by ISMV driven by an inwardly
directed proton gradient (pHout < pHin) (closed circlesd), and without
proton gradient (pHout = pHin) (opened circles s). The data shown
correspond to mean of triplicates (S.D. < 0.03) obtained in two
independent experiments.from a non-linear regression analysis using the SigmaPlot
9.0 Technical Graphing Software, values of Km and Vmax were
obtained and are presented in Table 1. In the presence of a pro-
ton gradient, an approximate Km of 0.48 mM was calculated, a
value much lower than the value of 1.40 mM obtained in the
absence of a proton gradient. These values suggest an increase
in substrate aﬃnity of the mediated pyruvate transport when a
proton force is driving the uptake. The Vmax was 5.5% higher
in the presence of a proton gradient.
3.2.2. Inhibitory eﬀect of diﬀerent VPA metabolites on the
uptake of [14C]-pyruvate. Fig. 4 shows the [14C]-pyruvate up-
take in ISMV in the presence of CHC, VPA, D4-VPA and the
respective CoA esters (VP-CoA and D4-VP-CoA).
The parent drug, VPA, and its unsaturated metabolite, D4-
VPA (both at 1 mM), had only a mild to insigniﬁcant eﬀect
on the mitochondrial uptake of pyruvate (22.0% and 15.7%
inhibition, respectively). However, at a higher concentration
(2 mM) only D4-VPA induced a signiﬁcant inhibition of the
pyruvate uptake rate (76.2% inhibition), as shown in Fig. 4A.
Furthermore, the uptake of pyruvate was also found to be
inhibited by both D4-VP-CoA (73.1% inhibition) and VP-
CoA (50.1% inhibition), in parallel with an increase of Km val-
ues for the pyruvate transport (Fig. 4B and Table 1).
Our results conﬁrm, by comparing all the tested compounds
at 1 mM, that CHC was in fact an eﬀective inhibitor of the
pyruvate uptake in ISMV (71.6% inhibition), as shown in
Fig. 4B and C.
Lactate, a substrate that potentially competes with pyruvate,
also inhibited this ketoacid uptake in ISMV (42.1% inhibition)
as depicted in Fig. 4A and C.
Table 1 summarises the kinetic parameters values of the
pyruvate uptake, calculated in the presence of the tested
VPA metabolites, CHC and lactate, as well as the obtained
inhibition (%) of control uptake values.4. Discussion
The transport of pyruvate across membranes plays a central
role in cellular metabolism and metabolic communication be-
Table 1
Eﬀect of diﬀerent inhibitors on the mitochondrial pyruvate uptake in ISMV
Kinetic parametersa pHout = pHin pHout < pHin
Control Control VPAb VP-CoAc D4-VPAc D 4-VP-CoAc CHCb Lactateb
Km 1.40 0.48 – – – – – –
Kappm – – 0.47 0.64 0.95 1.02 – –
Vmax 17.90 18.88 – – – – – –
V appmax – – 17.89 22.29 16.29 22.82 – –
Inhibition (%) – – 22.0 50.1 76.2 73.1 71.6 42.1
The values represent the apparent kinetic parameters (Kappm and V
app
max) and the average value of maximum inhibition (%) of the pyruvate uptake (100
minus % of control) in the presence of the respective inhibitors. Data shown are mean ± S.D. of triplicates of at least two independent experiments.
aValues of Km and Vmax are, respectively, expressed in mM and pmol/mg s.
b[Inhibitor] = 1 mM.
c[Inhibitor] = 2 mM.
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cells rely on the end product of glycolysis, i.e. pyruvate, to pro-
duce most of their ATP. This pathway occurs in the cell cyto-
sol, and thus the transport of pyruvate into the mitochondriafor further oxidation, is essential to fuel the citric acid cycle
after being converted into acetyl-CoA by pyruvate dehydroge-
nase [35,36]. For this purpose, the mitochondrial pyruvate car-
rier activity is critical for energy homeostasis.
3364 C.C.P. Aires et al. / FEBS Letters 582 (2008) 3359–3366The transport of monocarboxylates, such as pyruvate and
lactate across the plasma membrane is well-characterized and
catalysed by a recently identiﬁed family of proton-linked
monocarboxylate transporters [36]. In mitochondria, the mam-
malian pyruvate carrier has not yet been cloned, sequenced
and fully characterized, however, it has been considered as a
member of the six-transmembrane-helix mitochondrial carrier
family [15].
After the identiﬁcation of CHC as a speciﬁc and potent
inhibitor of the putative mitochondrial pyruvate carrier [6,9],
the existence of such protein has gained support by many stud-
ies and recently new highly potent inhibitors have been identi-
ﬁed [15,35,36].
The scope of this paper is primarily focused on functional
studies using a simple experimental model to test the direct ef-
fect of a speciﬁc drug and/or its metabolites on the mitochon-
drial uptake of pyruvate. This study was performed using
ISMV, which allowed a strict control of the driving force of
pyruvate uptake, by regulating both internal and external
pH. Furthermore, the approach was strictly focused on the
proton-dependent transport of pyruvate and no other internal
substrates were added, excluding other putative pyruvate
translocators. The former uptake experiments using intact
mitochondria and labelled pyruvate could not avoid the subse-
quent metabolism of the substrate inside the organelle, a fact
that would certainly aﬀect the pH and the osmolarity in the
matrix. The obtained homogeneity of the prepared ISMV
either in size or orientation, accounts for reproducible kinetic
measurements, at controlled conditions of pH.
Using this model, the results presented in this paper show
that pyruvate uptake decreases in ISMV in the absence of a
driving proton gradient, suggesting that the mitochondrial
transport of pyruvate is protein-mediated and coupled with a
proton-symport, as already proposed [2,36]. In addition,
CHC signiﬁcantly inhibited the uptake of this monocarboxy-
late in the prepared vesicles, supporting the previous hypothe-
sis. Furthermore, the uptake of pyruvate was inhibited in the
presence of lactate, suggesting that this compound may com-
pete with pyruvate into these vesicles.
In the present study, VPA and D4-VPA were found to clearly
inhibit the uptake of pyruvate in ISMV (as indicated by the
observed increase on the Km for pyruvate uptake). In addition,
our results suggest that the respective CoA esters of VPA and
D4-VPA are stronger inhibitors of the mitochondrial pyruvate
uptake than the parent drug (VPA). Both free acids were re-
cently found to be activated to the respective CoA esters not
only at the mitochondrial matrix, where the free acids are
prone to be metabolized by b-oxidation in the form of CoA es-
ters, but also in the extra-mitochondrial compartment [26].
The extra-mitochondrial formation of VP-CoA and D4-VP-
CoA may aﬀect numerous cellular functions, such as fatty-acid
elongation, peroxisomal metabolism, gluconeogenesis, urea-
genesis and many other pathways involving cytosolic reac-
tions. A targeted eﬀect of these CoA conjugates on the
mitochondrial pyruvate uptake is the hypothesis clearly sup-
ported by the present results.
Previous studies of our group have shown that oxygen con-
sumption and ATP synthesis driven by pyruvate was severely
decreased by VPA [1]. In addition, we recently reported that
VPA and D4-VPA also inhibit both 2-oxoglutarate and gluta-
mate-driven oxidation and ATP synthesis [37] although not so
strikingly as with pyruvate. The reported data suggest that theobserved inhibitory eﬀects of VPA and metabolites on mito-
chondrial ATP synthesis and oxidation of pyruvate, 2-oxoglu-
tarate and glutamate are likely due to an inhibitory eﬀect on
dihydrolipoamide dehydrogenase (DLDH, E3 subunit), the
common component of the multi-enzyme complexes 2-oxoglu-
tarate dehydrogenase, pyruvate dehydrogenase and branched-
chain 2-oxoacid dehydrogenase [37]. However, a speciﬁc eﬀect
on the transport systems in the mitochondrial inner membrane
could not be excluded. Thus, the defective import of pyruvate
into this organelle suggested by the present results mainly in-
duced by the respective CoA-esters (VP-CoA and D4-VP-
CoA), would be additive to the reported DLDH inhibition.
Being structurally related, those CoA esters do not diﬀuse in
membranes, due to their larger size and presence of double
bounds, and thereby they can potentially aﬀect pyruvate up-
take by interfering with the substrate binding-site or by mod-
ifying the protein transporter properties. Considering the free
acids, the data presented in this work suggest that the mono-
carboxylate anions, valproate and D4-valproate might enter
into the mitochondrial matrix by a symport process with H+,
competing with pyruvate for the same proton-linked trans-
porter. However, further studies are required in order to eluci-
date the mechanisms of the reported inhibition on the
mitochondrial uptake of pyruvate.
The present data do clearly support an inhibition of the
mitochondrial CHC-sensitive pyruvate/H+ symporter by
VPA and its derivatives. However, the eﬃcacy of other poten-
tial pyruvate uptake mechanisms, such as UCP1 and/or other
CHC-insensitive antiporter mechanisms [38–40] which may (or
may not) be inhibited by this drug, can possibly obviate a net
reduction in pyruvate transport in vivo.
The conversion of pyruvate to glucose, involving ﬁrstly its
uptake into mitochondria, is a crucial pathway in liver metab-
olism and a clear inhibition of gluconeogenesis from both lac-
tate and pyruvate by VPA and D4-VPA has long been
recognized [41,42]. The inﬂuence of VPA on carbohydrate
metabolism is undisputed, since a signiﬁcant weight-gain is
the most frequently reported adverse eﬀect of a long-term
VPA treatment [43,44], potentially associated with hyperinsu-
linemia and steatosis. In addition, the eﬀects of the drug on
fatty acid oxidation are well-documented [45] but their conse-
quences to the imbalance of glucose homeostasis are far from
being elucidated, considering the reciprocally linked mecha-
nisms of lipid and carbohydrate regulation in vivo.
Taken together, the present results may account for the lim-
ited oxidation of pyruvate previously observed, and thus to the
compromised energy production driven by this substrate in-
duced by VPA and/or metabolites.
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